en
Scientific article
English

Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial

Published inJAMA (Journal of the American Medical Association), vol. 315, no. 19, p. 2079-2085
Publication date2016
Abstract

Very preterm infants are at risk of developing encephalopathy of prematurity and long-term neurodevelopmental delay. Erythropoietin treatment is neuroprotective in animal experimental and human clinical studies.

Keywords
  • Child Development
  • Child, Preschool
  • Developmental Disabilities/prevention & control
  • Double-Blind Method
  • Drug Administration Schedule
  • Erythropoietin/administration & dosage
  • Female
  • Humans
  • Infant, Newborn
  • Infant, Premature
  • Intention to Treat Analysis
  • Male
  • Neurodevelopmental Disorders/prevention & control
  • Neuroprotective Agents/administration & dosage
  • Recombinant Proteins/administration & dosage
  • Treatment Outcome
Citation (ISO format)
NATALUCCI, Giancarlo et al. Effect of Early Prophylactic High-Dose Recombinant Human Erythropoietin in Very Preterm Infants on Neurodevelopmental Outcome at 2 Years: A Randomized Clinical Trial. In: JAMA (Journal of the American Medical Association), 2016, vol. 315, n° 19, p. 2079–2085. doi: 10.1001/jama.2016.5504
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal0098-7484
397views
0downloads

Technical informations

Creation09/27/2017 2:26:00 PM
First validation09/27/2017 2:26:00 PM
Update time03/15/2023 2:04:14 AM
Status update03/15/2023 2:04:13 AM
Last indexation01/17/2024 12:46:51 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack